What Does This Failure Mean for Eli Lilly Investors?
May 13th 2013 6:30PM
Updated May 13th 2013 7:25PM
Last week, pharmaceutical giant Eli Lilly announced that its cancer drug candidate enzastaurin failed its late-stage clinical trial. Despite this news, shares remained practically flat following the announcement. Was this drug central to Lilly's pipeline, or was it one of many oncology drugs that the company is testing? Should investors instead be worried about Lilly's upcoming patent expirations? What about the ever-present competition from diabetes powerhouseÂ Novo Nordisk ? Health-care analyst Max Macaluso discusses these topics in the following video.
Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.
The article What Does This Failure Mean for Eli Lilly Investors? originally appeared on Fool.com.Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.